235 related articles for article (PubMed ID: 34106911)
1. Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?
Yamshon S; Martin P
Clin Adv Hematol Oncol; 2021 Jun; 19(6):376-382. PubMed ID: 34106911
[TBL] [Abstract][Full Text] [Related]
2. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bond DA; Alinari L; Maddocks K
Clin Adv Hematol Oncol; 2019 Apr; 17(4):223-233. PubMed ID: 31188814
[TBL] [Abstract][Full Text] [Related]
3. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies in mantle cell lymphoma.
Hanel W; Epperla N
J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
[TBL] [Abstract][Full Text] [Related]
5. Novel therapies for relapsed/refractory mantle cell lymphoma.
Arora PC; Portell CA
Best Pract Res Clin Haematol; 2018 Mar; 31(1):105-113. PubMed ID: 29452660
[TBL] [Abstract][Full Text] [Related]
6. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
7. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
[TBL] [Abstract][Full Text] [Related]
8. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma.
Morabito F; Recchia AG; Vigna E; Botta C; Skafi M; Abu-Rayyan M; Atrash M; Galimberti S; Morabito L; Al-Janazreh H; Martino M; Cutrona G; Gentile M
Expert Opin Pharmacother; 2020 Jan; 21(1):29-38. PubMed ID: 31738609
[No Abstract] [Full Text] [Related]
9. Ibrutinib for mantle cell lymphoma.
Tucker DL; Rule SA
Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA; Cheah CY; Wang ML
Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
[TBL] [Abstract][Full Text] [Related]
11. Novel agents in mantle cell lymphoma.
Kumar A
Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
[TBL] [Abstract][Full Text] [Related]
12. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Bond DA; Maddocks KJ
Hematol Oncol Clin North Am; 2020 Oct; 34(5):903-921. PubMed ID: 32861286
[TBL] [Abstract][Full Text] [Related]
13. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
14. Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
Agarwal R; Dawson MA; Dreyling M; Tam CS
Leuk Lymphoma; 2018 Dec; 59(12):2769-2781. PubMed ID: 29912596
[TBL] [Abstract][Full Text] [Related]
15. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
[TBL] [Abstract][Full Text] [Related]
16. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
[TBL] [Abstract][Full Text] [Related]
18. Combating relapsed and refractory Mantle cell lymphoma with novel therapeutic armamentarium: Recent advances and clinical prospects.
Raghani NR; Shah DD; Shah TS; Chorawala MR; Patel RB
Crit Rev Oncol Hematol; 2023 Oct; 190():104085. PubMed ID: 37536448
[TBL] [Abstract][Full Text] [Related]
19. The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
Hanna KS; Campbell M; Husak A; Sturm S
J Oncol Pharm Pract; 2020 Jul; 26(5):1190-1199. PubMed ID: 32279595
[TBL] [Abstract][Full Text] [Related]
20. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
Nabrinsky E; Danilov AV; Koller PB
Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
